MOG and myeloid sarcoma: To evaluate the potential clinical utility of Fc multimers in MS, we tested the efficacy of M019 in reducing symptoms of EAE using the C57BL/6 (B6) model of MOG-induced EAE which mimics chronic neuroinflammation.